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From a neurochemical perspective, depressed patients often have a chronically heightened sympathetic state. 5 This has been attributed to putative mechanism such as β-adrenoreceptor down-regulation and abnormal 5-hydroxytryptamine (5-HT) receptor activity in the brain. 5, 6 It is now known that brain serotonin, a neurotransmitter with central sympathoinhibitory properties, is reduced in depression and could result in overexpression of sympathetic neural discharge. 7 Heart rate variability (HRV) offers a unique noninvasive window through which to visualize the effects of centrally mediated changes in autonomic modulation of cardiac function. 8 It follows that by use of this technology it is possible to assess changes in cardiac sympathomodulation over time, using serial changes in HRV. Interestingly, it is known that reduced HRV, one of the consequences of sympathoexcitation, is, as in depression, an independent predictor of mortality within the first year of an acute MI. 9 Moreover, several studies have Major and minor depressive disorders are common, with lifetime prevalence rates of 5% and 13%, respectively. 1 It is now recognized that depressed patients having an acute myocardial infarction (MI) are particularly predisposed to major adverse outcome within the first year of the acute event. 2, 3 In a recent study FrasureSmith et al reported an 18% and 27% incidence of major and minor depression, respectively, in patients recovering from an acute MI. 4 Moreover, the hazards ratio for death within 6 months of the acute event was 5-fold among a depressed compared with a nondepressed cohort. Although this association is a matter of growing concern, neither the mechanisms nor the effect of anti-demonstrated a shift in sympathovagal balance toward a heightened sympathetic state in patients with depression. [10] [11] [12] Our working model presumes that linkages exist between the stress of an acute MI, either onset or exacerbation of depression, cardiac autonomic imbalance, and adverse clinical outcomes. Several studies have demonstrated a gradual recovery of cardiac autonomic function within 2 to 12 months after an acute MI. 13, 14 Given that most serious outcome events occur within the first 6 months of hospital discharge, it is reasonable to assume that any intervention that rapidly returns autonomic balance in patients with persistent depressive symptoms could stabilize the heart, thereby rendering it less vulnerable to malignant ventricular arrhythmias. In this randomized, placebo-controlled clinical physiologic study, we set out to determine the effect of sertraline, a selective serotonin reuptake inhibitor (SSRI), on the rate of recovery of heart rate variability in depressed patients who had had an acute MI.
Methods

Study population
Between September 1996 and March 1999, 238 patients admitted with an acute MI to our coronary care unit (CCU) completed a standardized questionnaire designed to assess depression. Eighty-six percent or 36% scored above a predetermined threshold that satisfied criteria for inclusion of both minor and major depression. Of these, 38 (44%) agreed to enter a double-blind, randomized, placebo-controlled trial of sertraline 50 mg per day for 6 months. Eleven dropped out after randomization within the first 2 months (6 in the sertraline group and 5 in the placebo group), 3 because of drug side effects, 7 because of noncompliance, and 1 because of frequent ventricular ectopy. Of the 27 patients who completed the study, the average age was 62 ± 11 (SD) years and 16% or 59% were male. Eleven age-matched nondepressed post-MI patients (9 male, age 62 ± 12 years) served as a nonrandomized reference group to ascertain the "normal" rate of recovery of cardiac autonomic function in an otherwise nondepressed cohort. Excluded were patients whose predischarge 24-hour Holter recordings showed either atrial fibrillation or ventricular ectopic beats greater than 100 per hour. Also excluded were patients with overt congestive heart failure, any life-threatening comorbid condition, an inability to complete the questionnaire, and those already on antidepressant medications.
Study protocol
The design was a double-blind, randomized, placebo-controlled trial with stratification before randomization for those on β-blocker therapy. Patients meeting the inclusion criteria for randomization had to score >15 on the Inventory to Diagnose Depression (IDD) questionnaire (vide infra) at least twice, once just before hospital discharge and again 2 weeks later. This was to ensure stability in their mood alteration. The 38 patients were then randomized to receive either sertraline 50 mg a day or a matched placebo tablet. There was, in addition, a third group, a nondepressed nonrandomized reference group (n = 11) whose IDD score had to be less than 15.
All 3 groups had baseline measurements of HRV 2 weeks after MI before sertraline or placebo was initiated. These included short-term supine and standing power spectral indices of HRV under controlled laboratory conditions as well as time domain statistics derived from 24-hour ambulatory electrocardiogram (ECG) Holter recordings. All 3 groups were then followed up by one nurse practitioner (V. M.) in a special post-MI clinic (PMIC) at McMaster University Medical Centre for 6 months. The PMIC is a multidisciplinary clinic with uniform standards of follow-up care for those discharged from our CCU, providing access to exercise rehabilitation, nutritional counseling, smoking cessation programs, and supportive psychotherapy. Hence all 3 groups received the same level of care throughout in the same clinic with the same caretaker(s). Each patient underwent identical 24-hour Holter and laboratory testing at 2, 6, 10, 14, 18, and 22 weeks after MI. IDD testing was repeated at 6, 10, 18, and 22 weeks. The research protocol was approved by the Institutional Review Board of the Faculty of Health Sciences of McMaster University. All patients gave written informed consent.
IDD
The IDD is a self-completion instrument developed by Zimmerman et al. 15 It covers all Diagnostic Statistical Manual's criteria for major depressive disorder. It uses thresholds to determine the presence or absence of symptoms, each item being graded for severity as well as duration. The IDD is highly reliable with a sensitivity of 81% to detect major depressive disorder. It correlates well with the Beck Depression Inventory (0.87), the Hamilton Rating Scale (0.80), and the Depression Interview Schedule (κ 0.9). The IDD is especially useful in measuring severity of depressive symptoms with changes over time. 16 
HRV
For the time domain analysis, each 24-hour Holter tape was first annotated with an Oxford Medilog Excel scanner. A beatto-beat recognition software algorithm was assigned a configuration class to each QRS complex. The normal sinus-conducted N-N interbeat intervals were then downloaded for offline computational analysis. This included the average heart rate, the SD of all 24-hour N-N intervals (SDNN), and the root mean square of the SD of successive N-N intervals (rMSSD). The power spectrum of HRV was computed by autoregressive modeling. This test was performed under carefully controlled laboratory conditions with a customized acquisition analog-to-digital system. A full description of our method can be found in a previous report. 17 In brief, the filtered ECG signal (2.2 minutes) was digitized with a 12-bit analog-to-digital converter at a sampling rate of 1 kHz. The instantaneous heart rate series was resampled by linear interpolation to obtain an equally sampled signal spaced 0.5 seconds apart. The power spectrum was then computed from the HRV data of 256 samples. An autoregressive model of order number 14 was fitted to the HRV signal. Both the peak amplitude and the normalized area power contained in the low-frequency (LF) (0.05-0.15 Hz) and the high-frequency (HF) (0.15-0.40 Hz) bands were derived. Because of anticipated low energies in signals from patients with poor left ventricular (LV) function, all patients were studied in both the supine (20-30 minutes) and standing (10 minutes) positions to maximize the signal-to-noise ratio in the LF band as well as to assess, indirectly, a measure of baroreceptor function.
Outcome measurements and data analysis
The primary outcome measurements were the time-dependent changes in both time and frequency domain parameters of HRV. To estimate the rate of recovery of autonomic function, we used a growth curve model based on a repeated-measures analysis of variance (ANOVA). 18 With this method the data are fitted to a linear equation containing a polynomial function of time, dummy variable for the sertraline versus placebo group, and interactions. The functional form was
where X is a dummy variable equal to 0 for the placebo group and 1 for the sertraline group and t is elapsed time from initiation of treatment. Initial analysis also included quadratic and cubic terms (and interactions), but these were not significant and were omitted from the reported analysis. Finally, a test of significance was conducted by dividing each coefficient by its SE. The analyses were conducted by use of a standard statistical package (BMDPV, Los Angeles, Calif). All data are expressed as mean ± SEM. Baseline differences were analyzed by 1-way ANOVA and comparisons of the direction of orthostatic changes in LF power between the depressed and nondepressed reference group were computed using χ 2 analysis. A value of P < .05 was considered significant.
Results
Baseline demographic and clinical characteristics were similar between the sertraline and placebo groups (Table I) . Both groups had well-preserved LV function with ejection fractions averaging 53% and 58% for the active treatment and placebo groups, respectively. There were no significant group differences for risk factors, cardiac medications, revascularization procedures, thrombolysis, or history of previous MI. The IDD scores (range 16-43) averaged 21 ± 6.7 and 23 ± 6.4 for the sertraline and placebo group, respectively. It was only in the sertraline-treated group that a significant decrease in IDD scores (21 to 16, P < .05) was seen at the end of 22 weeks (Figure 1) .
Similarly, there were no significant baseline differences in any of the HRV measurements between the study groups (Table II) . There appeared to be a more robust HRV in the nondepressed reference group whose reduced LF/HF ratio, slower heart rate, and higher rMSSD suggest a comparatively higher vagal state. These baseline differences, however, did not reach statistical significance. On the other hand, there was a distinct difference between the depressed patients and their nondepressed counterparts with respect to the ability to mount a baroreceptor-mediated response to orthostatic stress (Figure 2) . Although only 1 nondepressed patient failed to increase his LF power on standing erect, >50% (16/27) of the depressed group actually exhibited an abnormal decrease in LF power with orthostasis (P < .05).
The most striking finding was an increase in SDNN in the sertraline-treated group in contrast to the steady decline in SDNN in the placebo group ( Figure 3 and Table III ). During the 22 weeks after the acute infarction, the average SDNN for the sertraline group increased a modest 5% from 110.6 ± 10.1 milliseconds to 115.4 ± 11.0 seconds. Conversely, the depressed patients treated with placebo showed a 9% decrease in SDNN. This difference in the trends of the sertraline versus placebo groups was confirmed by growth curve analysis where the test of the group × time interaction was significant IDD scores for sertraline-treated and placebo groups at baseline and at 22 weeks after MI. Asterisk, Significant drop in score, P < .1 (t = 2.10, P < .05). In all instances the same individual patients contributed to the mean values at every time period. During this same interval, it can be seen that the nondepressed group showed a 28% increase in SDNN from 108 ± 8.6 to 138 ± 12 milliseconds. Although no significant group differences were seen in time trends for any of the remaining HRV parameters (Table III) there were nevertheless 2 interesting observations. First, in all 3 groups both time and frequency domain HRV indices were not static but displayed linear trends over time, indicating a progressive recovery toward normalization of autonomic balance. Second, although sertraline did not appear to influence the rate of recovery of either the LF/HF ratio or the resting supine LF power in the depressed groups, there was a persistent and significant reduction in LF power indices in the nondepressed compared with either of the depressed groups throughout the followup period (Table III) .
At the end of 6 months there was a 26% reduction in IDD scores in the sertraline group (22.25 ± 2.0 to 16.5 ± 1.5, P < .05) compared with no change in the placebo group (23 ± 2.1 to 27 ± 8). However, there was no significant correlation between the baseline IDD scores and any of the HRV measurements. Neither was there a correlation between changes in IDD scores over time and time-dependent changes in any HRV index. Although it was not the purpose of the study to measure clinical outcomes, the sample size being too small, we note there were no deaths in any of the groups during 6 months of follow-up, and the number of patients requiring readmission for either unstable angina or reinfarction was too small to draw any statistical inferences. Of note, sertraline was well tolerated with no adverse reactions or clinical symptoms among those who completed the study. Table II . HRV data at baseline
Figure 2
Comparison of the orthostatic responses of the LF power between the depressed (n = 27) and nondepressed (n = 11) groups at baseline. Solid bars, Depressed group; open bars, nondepressed group. Positive and negative refer to directional changes (increases or decreases respectively) of the LF power from supine to standing states. There were significantly more abnormal responses (ie, a fall in LF power on standing) in the depressed group (χ 2 P < .05).
Figure 3
Growth curve plots of the rate of recovery of SDNN (in milliseconds) conform to a linear model represented by the sertraline (dashed line), placebo (solid line), and nondepressed (dotted line) groups. Base on the abscissa refers to baseline (2 weeks after acute MI). The differences in rate of recovery between the sertraline-treated and placebo group are statistically significant (t = 2.10, P < .05).
Discussion
This study shows that, in depressed patients after acute MI, sertraline facilitates the rate of recovery of SDNN, a potent predictor of cardiac mortality. For the sertraline-treated group the trend toward restoring autonomic balance paralleled that of the nondepressed group. These rates of recovery were not dissimilar from those reported by Bigger et al 13 and Lombardi et al. 14 Conversely, the depressed group on placebo demonstrated a modest but persistent decline in SDNN throughout the 6 months of follow-up.
Much has been written about the worrisome impact of depression on adverse outcomes after MI. 20 Post hoc analysis of data from several large clinical trials shows a strong correlation between psychosocial factors and cardiac outcome events including sudden death. 19, 20 These and other studies support previous claims that depression confers a mortality risk as high as 4-to 6-fold within a year or so of an acute MI. 21, 22 Depression therefore emerges as a potent risk factor even after correction for known covariates such as LV dysfunction, previous MI, and ventricular arrhythmias.
A causal link is harder to unravel. In terms of physiologic mechanisms, it is now accepted that depression is associated with a heightened sympathetic state. 5 This may be related to down-regulation of central postsynaptic β-adrenoreceptors or changes in activity of serotonin 5-HR 2 receptors in the brain. 6, 23 With depression, chronic depletion of neurotransmitters such as serotonin in central synaptic clefts could lead to interruption of inhibitory inputs to central sympathetic centers, thereby increasing sympathetic neural discharge. It has been shown that stimulation of central 5-HT 1A receptors can also lead to sympathoexcitation. 23 Autonomic regulation of cardiac function is usually expressed by noninvasive measurements of HRV. Both time and frequency domain indices of HRV are powerful independent predictors of mortality within the first year after MI. 9, 24 A relationship between depression and HRV has also been well documented. Carney et al 25 reported that HRV, expressed as SDNN, was significantly lower in patients with coronary disease with depression compared with nondepressed patients even after correction for known covariates. Rechlin et al, 10 using both time and frequency domain measures in patients with major depression, reported significantly lower values of SDNN and HF (vagal) power with little or no differences seen in a control group with reactive depression.
Given these observations, one could make a case that because antidepressants significantly improve HRV parameters they should, at least theoretically, improve clinical outcomes. Much depends on the cardiovascular effects of antidepressants generally and their influence specifically on cardiac autonomic regulation. In contrast to tricyclic antidepressants, which can cause tachyarrhythmias, the SSRIs are well tolerated and possess no anticholinergic effects and no effect on peripheral autonomic tone such as postural hypotension, and they are not proarrhythmic. Balogh et al 26 27 compared the effect of both doxepine and fluoxetine on 24-hour HRV measurements over 6 weeks. Using the Hamilton Depression Rating Scale they found that among the 10 of 14 patients responding to treatment there was a 17% increase in SDNN, whereas an actual decrease in SDNN was seen in the nonresponders. Although their population was noncardiac, our study showed similar findings in post-MI patients insofar as a significant increase in SDNN was observed in the sertraline treatment in post-MI patients whereas an actual decrease in SDNN occurred over time in the placebo group. In an interesting study of patients with panic disorder, Tucker et al 28 observed a positive effect of fluoxetine on baroreceptor responsiveness as determined by the LF power response to orthostasis. We saw a trend toward an increase in the orthostatic effect on LF power over time, but the differences between the sertraline-treated and placebo groups did not reach statistical significance. Of interest, however, was the distinct impairment of the orthostatic (baroreceptor) response in both depressed groups before randomization. These findings lend credence to the notion that early treatment of depression significantly improves HRV parameters, a known risk factor for adverse post-MI outcomes. Potential limitations of this study deserve comment. First, the autonomic changes seen with sertraline were not evident for all HRV parameters. For instance, there were only modest changes in rMSSD for any group. It should be noted, however, that rMSSD is a differencing method that primarily characterizes vagally mediated responses. It is of interest, therefore, that both depressed cohorts exhibited lower rMSSD values compared with the nondepressed group consistently throughout the follow-up period. Although the power spectral measurements were performed under laboratory-controlled conditions to ensure stationarity, it is important to be aware they are known to have less intraindividual reproducibility over time compared with the more robust SDNN. 29 The LF power for instance, whether normalized or no, represents a small portion (about 4%) of the total power contained in the daily 24-hour signal. And yet this index, primarily of sympathetic origin, did decrease over time for both depressed groups and paralleled the LF changes seen in the nondepressed group. More than 60% of the patients were on β-blockers. It is well known that these agents can attenuate the power contained in the LF band 30, 31 and thus may have influenced the modest changes seen in the power spectral indices. For this reason we took care to stratify all patients on β-blockers before randomization. Apropos any possible interaction between SSRI agents and β-blockers, Ziegler and Wilner 32 showed that sertraline had no effect on the chronotropic response to exercise in patients on β-blocker therapy. One of the major problems with drawing comparisons between studies that use different methods is the lack of a common gold standard, a problem particularly pertinent to both HRV measurements and instruments for diagnosing depression. In this respect, measures of HRV parameters in this report assiduously followed the guidelines recommended in the task force report of 1996. 33 In conclusion, our study shows that sertraline, a central serotonin reuptake inhibitor, facilitates the rate of recovery of HRV, an expression of cardiac autonomic function, in depressed patients after an MI. The clinical relevance of these findings deserves comment. There is often a tendency to ascribe a critical physiologic role to potent prognostic variables such as HRV as if iatrogenic modification of the variable would necessarily have an impact on prognosis. This may or may not be the case because the variable may simply be a surrogate or epiphenomenon rather than a direct precipitant of outcome events. Given this caution, the results reported here nonetheless help advance the notion that SSRIs may play an important therapeutic role for susceptible depressed patients recovering from an acute MI. Accordingly, they are worthy of being tested in larger and longer-term clinical trials. 34 
